English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/146182
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Adduct formation and context factors in drug hypersensitivity: insight from proteomic studies

Other TitlesProteomics in drug hypersensitivity
AuthorsGonzález-Morena, Juan M.; Montañez, M. I.; Aldini, Giancarlo; Sánchez-Gómez, Francisco J. ; Pérez-Sala, Dolores
KeywordsDrug allergy
Protein haptenation
Amoxicillin
Proteomics
Oxidative stress
Issue Date2016
PublisherBentham Science Publishers
CitationCurr Pharm Des 22 (45) 6748-6758 (2016)
AbstractDrug hypersensitivity reactions result from the activation of the immune system by drugs or their metabolites. The clinical presentations of drug hypersensitivity can range from relatively mild local manifestations to severe systemic syndromes that can be life-threatening. As in other allergic reactions, the causes are multifactorial as genetic, metabolic and concomitant factors may influence the occurrence of drug hypersensitivity. Formation of drug protein adducts is considered a key step in drug adverse reactions, and in particular in the immunological recognition in drug hypersensitivity reactions. Nevertheless, non-covalent interactions of drugs with receptors in immune cells or with MHC clefts and/or exposed peptides can also play an important role. In recent years, development of proteomic approaches has allowed the identification and characterization of the protein targets for modification by drugs in vivo and in vitro, the nature of peptides exposed on MHC molecules, the changes in protein levels induced by drug treatment, and the concomitant modifications induced by danger signals, thus providing insight into context factors. Nevertheless, given the complexity and multifactorial nature of drug hypersensitivity reactions, understanding the underlying mechanisms also requires the integration of knowledge from genomic, metabolomic and clinical studies.
Description21 p.-4 fig.-1 tab.
Publisher version (URL)http://dx.doi.org/10.2174/1381612822666160927113748
URIhttp://hdl.handle.net/10261/146182
DOI10.2174/1381612822666160927113748
ISSN1381-6128
E-ISSN1873-4286
Appears in Collections:(CIB) Artículos
Files in This Item:
File Description SizeFormat 
Current Pharm. Design_Perez-Sala 2016.pdfPostprint870,1 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.